Document:

Form of Stock Option Agreement under 2004 Stock Incentive Plan

 EXHIBIT 10.8 
  
 INTRALASE CORP. 
  
 STOCK OPTION AGREEMENT 
  

					
	Type of Option (check one):	 	  ̈        Incentive
	 	  ̈        Nonqualified

  
 This Stock Option
Agreement (the “Agreement”) is entered into as of             , 200  , by and between IntraLase Corp., a Delaware corporation (the “Company”),
and
                                        
                 (the “Optionee”) pursuant to the Company’s 2004 Stock Incentive Plan (the “Plan”). Any capitalized term not defined herein
shall have the same meaning ascribed to it in the Plan. 
  
 1.
Grant of Option. The Company hereby grants to Optionee an option (the “Option”) to purchase all or any portion of a total of _____________________________ (__________) shares (the “Shares”) of the Common Stock
of the Company at a purchase price of _________________________ ($__________) per share (the “Exercise Price”), subject to the terms and conditions set forth herein and the provisions of the Plan. If the box marked “Incentive”
above is checked, then this Option is intended to qualify as an “incentive stock option” as defined in Section 422 of the Internal Revenue Code of l986, as amended (the “Code”). If this Option fails in whole or in part to qualify
as an incentive stock option, or if the box marked “Nonqualified” is checked, then this Option shall to that extent constitute a nonqualified stock option. 
  
 2. Vesting of Option. The right to exercise this Option shall vest in installments, and this Option
shall be exercisable from time to time in whole or in part as to any vested installment, as follows: 
  
 This Option shall: 
  

			
	 On or After:

	 	 Be Exercisable As To:

	(i) the first anniversary of this Agreement:	 	25% of the Shares
		
	(ii) the final day of each month thereafter:	 	an additional 2.083% of the Shares

  
 No additional Shares
shall vest after the date of termination of Optionee’s “Continuous Service” (as defined in Section 3 below), but this Option shall continue to be exercisable in accordance with Section 3 hereof with respect to that number of shares
that have vested as of the date of termination of Optionee’s Continuous Service (as defined in Section 3 below). 
  
 3. Term of Option. Optionee’s right to exercise this Option shall terminate upon the first to occur of the following:

  
 (a) the expiration of ten (10) years from the
date of this Agreement; 
  
 (b) the expiration of
three (3) months from the date of termination of Optionee’s Continuous Service if such termination occurs for any reason other than permanent 

  

 
disability or death; provided, however, that if Optionee dies during such three-month period the provisions of Section 3(d) below shall apply; 
  
 (c) the expiration of one (1) year from the date of
termination of Optionee’s Continuous Service if such termination is due to permanent disability of the Optionee (as defined in Section 22(e)(3) of the Code); 
  
 (d) the expiration of one (1) year from the date of termination of Optionee’s Continuous Service if
such termination is due to Optionee’s death or if death occurs during the three-month period following termination of Optionee’s Continuous Service pursuant to Section 3(b) above; or 
  
 (e) upon the consummation of a “Change in Control”
(as defined in Section 2.6 of the Plan), unless otherwise provided pursuant to Section 8 below. 
  
 As used herein, the term “Continuous Service” means (i) employment by either the Company or any parent or subsidiary corporation of the Company,
or by a corporation or a parent or subsidiary of a corporation issuing or assuming a stock option in a transaction to which Section 424(a) of the Code applies, which is uninterrupted except for vacations, illness (except for permanent disability, as
defined in Section 22(e)(3) of the Code), or leaves of absence which are approved in writing by the Company or any of such other employer corporations, if applicable, (ii) service as a member of the Board of Directors of the Company until Optionee
resigns, is removed from office, or Optionee’s term of office expires and he or she is not reelected, or (iii) so long as Optionee is engaged as a consultant or service provider to the Company or other corporation referred to in clause (i)
above. 
  
 4. Exercise of Option. On or after
the vesting of any portion of this Option in accordance with Sections 2 or 8 hereof, and until termination of the right to exercise this Option in accordance with Section 3 above, the portion of this Option which has vested may be exercised in whole
or in part by the Optionee (or, after his or her death, by the person designated in Section 5 below) upon delivery of the following to the Company at its principal executive offices: 
  
 (a) a written notice of exercise which identifies this Agreement and states the number of Shares then being
purchased (but no fractional Shares may be purchased); 
  
 (b) a check or cash in the amount of the Exercise Price (or payment of the Exercise Price in such other form of lawful consideration as the Administrator may approve from time to time under the provisions of Section 5.3 of the Plan);

  
 (c) a check or cash in the amount reasonably
requested by the Company to satisfy the Company’s withholding obligations under federal, state or other applicable tax laws with respect to the taxable income, if any, recognized by the Optionee in connection with the exercise of this Option
(unless the Company and Optionee shall have made other arrangements for deductions or withholding from Optionee’s wages, bonus or other compensation payable to Optionee, or by the withholding of Shares issuable upon exercise of this Option or
the delivery of Shares owned by the Optionee in accordance with Section 12.1 of the Plan, provided such arrangements satisfy the requirements of applicable tax laws); and 
  

 2 

 (d) a letter, if requested by the Company, in such form and substance as the Company may
require, setting forth the investment intent of the Optionee, or person designated in Section 5 below, as the case may be. 
  
 5. Death of Optionee; No Assignment. The rights of the Optionee under this Agreement may not be assigned or transferred except by
will or by the laws of descent and distribution, and may be exercised during the lifetime of the Optionee only by such Optionee. Any attempt to sell, pledge, assign, hypothecate, transfer or dispose of this Option in contravention of this Agreement
or the Plan shall be void and shall have no effect. If the Optionee’s Continuous Service terminates as a result of his or her death, and provided Optionee’s rights hereunder shall have vested pursuant to Section 2 hereof, Optionee’s
legal representative, his or her legatee, or the person who acquired the right to exercise this Option by reason of the death of the Optionee (individually, a “Successor”) shall succeed to the Optionee’s rights and obligations under
this Agreement. After the death of the Optionee, only a Successor may exercise this Option. 
  
 6. Representation of Optionee. Optionee acknowledges receipt of a copy of the Plan and understands that all rights and obligations connected with this Option are set forth in this Agreement and
the Plan. 
  
 7. “Market Stand-Off”
Agreement. Optionee hereby agrees that during the period of duration specified by the Company and an underwriter of Common Stock or other securities of the Company, following the effective date of a registration statement of the Company
filed under the Securities Act, it shall not, to the extent requested by the Company and such underwriter, directly or indirectly sell, offer to sell, contract to sell (including, without limitation, any short sale), grant any option to purchase or
otherwise transfer or dispose of (other than to donees who agree to be similarly bound) any securities of the Company held by it at any time during such period except Common Stock included in such registration; provided, however, that: 

 
 (a) such agreement shall be applicable only to the
registration statement of the Company which covers Common Stock to be sold on its behalf to the public in (i) the Company’s initial firm commitment underwritten public offering of equity securities, and (ii) any firm commitment underwritten
public offering of equity securities subject to a registration statement the effective date of which is within 12 months of the effective date of the first registration statement for a public offering of the securities of the Company; 
  
 (b) such market stand-off time period shall not exceed 180
days; and 
  
 (c) such agreement shall not apply
to the sale of any shares to such underwriter pursuant to an underwriting agreement. 
  
 In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to the Shares of Optionee (and the shares or securities of every other person subject to the foregoing
restriction) under the end of such period. 
  
 8.
Adjustments Upon Changes in Capital Structure. In the event that the outstanding shares of Common Stock of the Company are hereafter increased or decreased or changed into or exchanged for a different number or kind of shares or
other securities of the Company by reason of a recapitalization, stock split, combination of shares, reclassification, stock dividend or other change in the capital structure of the Company, then appropriate adjustment shall be made by the
Administrator 

  

 3 

 
to the number of Shares subject to the unexercised portion of this Option and to the Exercise Price per share, in order to preserve, as nearly as practical,
but not to increase, the benefits of the Optionee under this Option, in accordance with the provisions of Section 4.3 of the Plan. 
  
 9. Change in Control. In the event of a Change in Control (as defined in Section 2.6 of the Plan): 
  
 (a) The right to exercise this Option shall accelerate
automatically and vest in full (notwithstanding the provisions of Section 2 above) effective as of immediately prior to the consummation of the Change in Control unless this Option is to be assumed by the acquiring or successor entity (or parent
thereof) or a new option or New Incentives are to be issued in exchange therefor, as provided in subsection (b) below. If vesting of this Option will accelerate pursuant to the preceding sentence, the Administrator in its discretion may provide, in
connection with the Change in Control transaction, for the purchase or exchange of this Option for an amount of cash or other property having a value equal to the difference (or “spread”) between: (x) the value of the cash or other
property that the Optionee would have received pursuant to the Change in Control transaction in exchange for the Shares issuable upon exercise of this Option had this Option been exercised immediately prior to the Change in Control minus (y) the
aggregate Exercise Price for such Shares. If the vesting of this Option will accelerate pursuant to this subsection (a), then the Administrator shall cause written notice of the Change in Control transaction to be given to the Optionee not less than
fifteen (15) days prior to the anticipated effective date of the proposed transaction. 
  
 (b) The time period relating to the exercise or realization of [twenty-five percent (25%) / fifty percent (50%)] of the outstanding
unvested Options hereunder at the time of a Change of Control of the Company shall accelerate if and to the extent that: (i) this Option (including the unvested portion thereof) is to be assumed by the acquiring or successor entity (or parent
thereof) or a new option of comparable value is to be issued in exchange therefor pursuant to the terms of the Change in Control transaction, or (ii) this Option (including the unvested portion thereof) is to be replaced by the acquiring or
successor entity (or parent thereof) with other incentives of comparable value under a new incentive program (“New Incentives”) containing such terms and provisions as the Administrator in its discretion may consider equitable. If this
Option is assumed, or if a new option of comparable value is issued in exchange therefor, then this Option or the new option shall be appropriately adjusted, concurrently with the Change in Control, to apply to the number and class of securities or
other property that the Optionee would have received pursuant to the Change in Control transaction in exchange for the Shares issuable upon exercise of this Option had this Option been exercised immediately prior to the Change in Control, and
appropriate adjustment also shall be made to the Exercise Price such that the aggregate Exercise Price of this Option or the new option shall remain the same as nearly as practicable. 
  
 (c) If the provisions of subsection (b) above apply, then this Option, the new option or the New Incentives
shall with respect to the remaining unvested Options continue to vest and become exercisable thereafter in installments on each vesting date in accordance with the provisions of Section 2 hereof, each such installment to be reduced by a pro-rata
portion of the Options which have become exercisable as set forth in Section 8(b), and shall continue in effect for the remainder of the term of this Option in accordance with the provisions of Section 3 hereof. However, in the event of an
Involuntary Termination (as defined in the Plan) of Optionee’s Continuous Service within twelve (12) months following such Change in Control, then vesting of this Option, the new option or the New Incentives shall accelerate [OPTION ONE –
OFFICERS AND 

  

 4 

 
DIRECTORS: in full automatically effective upon such Involuntary Termination. OPTION TWO – ALL OTHERS: by
            % automatically effective upon such Involuntary Termination.] 
  
 10. No Employment Contract Created. Neither the granting of this Option nor the exercise hereof shall be construed as granting to the
Optionee any right with respect to continuance of employment by the Company or any of its subsidiaries. The right of the Company or any of its subsidiaries to terminate at will the Optionee’s employment at any time (whether by dismissal,
discharge or otherwise), with or without cause, is specifically reserved. 
  
 11. Rights as Stockholder. The Optionee (or transferee of this option by will or by the laws of descent and distribution) shall have no rights as a stockholder with respect to any Shares covered
by this Option until the date of the issuance of a stock certificate or certificates to him or her for such Shares, notwithstanding the exercise of this Option. 
  

12. Notice of Disqualifying Disposition. To obtain certain tax benefits afforded to Incentive Options, an Optionee must hold the shares
issued upon the exercise of an Incentive Option for two years after the date of grant of the Option and one year from the date of exercise. By executing this Agreement, Optionee hereby agrees to promptly notify the Company’s Chief Financial
Officer of any disposition of Shares within one year from the date this Option is exercised or within two years of the date of grant of this Option. 
  
 13. Interpretation. This Option is granted pursuant to the terms of the Plan, and shall in all respects be interpreted in accordance
therewith. The Administrator shall interpret and construe this Option and the Plan, and any action, decision, interpretation or determination made in good faith by the Administrator shall be final and binding on the Company and the Optionee. As used
in this Agreement, the term “Administrator” shall refer to the committee of the Board of Directors of the Company appointed to administer the Plan, and if no such committee has been appointed, the term Administrator shall mean the Board of
Directors. 
  
 14. Notices. Any
notice, demand or request required or permitted to be given under this Agreement shall be in writing and shall be deemed given when delivered personally or three (3) days after being deposited in the United States mail, as certified or registered
mail, with postage prepaid, (or by such other method as the Administrator may from time to time deem appropriate), and addressed, if to the Company, at its principal place of business, Attention: the Chief Financial Officer, and if to the Optionee,
at his or her most recent address as shown in the employment or stock records of the Company. 
  
 15. Governing Law. This Agreement shall be construed in accordance with the laws of the State of Delaware without reference to choice
of law principles, as to all matters, including, but not limited to, matters of validity, construction, effect or performance. 
  
 16. Severability. Should any provision or portion of this Agreement be held to be unenforceable or invalid for any reason, the
remaining provisions and portions of this Agreement shall be unaffected by such holding. 
  
 17. Attorneys’ Fees. If any party shall bring an action in law or equity against another to enforce or interpret any of the terms, covenants and provisions of this Agreement, the prevailing
party in such action shall be entitled to recover from the other party reasonable attorneys’ fees and costs. 
  

 5 

 18. Counterparts. This Agreement may be executed in two or more counterparts, each
of which shall be deemed an original and all of which together shall be deemed one instrument. 
  
 [Signature Page Follows] 
  

 6 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

  

									
	 INTRALASE CORP.
 a Delaware corporation
	 	 	 	     OPTIONEE

					
	 By:
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	(Signature)
					
	 Its:
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	(Type or print name)
				
	 	 	 	 	 	 	     Address:

					
	 	 	 	 	 	 	 	 	 
					
	 	 	 	 	 	 	 	 	 

  

 7Patent License Agreement

 EXHIBIT 10.11 
  
 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such
omissions. 
  
 PATENT LICENSE AGREEMENT 
  
 between 
  
 AGERE SYSTEMS GUARDIAN CORPORATION 
  
 and 
  
 INTRALASE CORP. 
  
 Effective December 31, 2001 
  
 Relating to 
  
 LASER
OSCILLATOR SUBSYSTEMS 

 Table of Contents 
  

					
	 	  	 	  	Page

	 ARTICLE I
	  	 GRANTS OF LICENSES
	  	1
	       1.01
	  	 Grant
	  	1
	       1.02
	  	 Duration
	  	1
	       1.03
	  	 Licensing Provisions
	  	1
	       1.04
	  	 Ability to Provide Licenses
	  	2
	       1.05
	  	 Joint Inventions
	  	2
	       1.06
	  	 Publicity
	  	3
	       1.07
	  	 Confidentiality
	  	3
			
	 ARTICLE II
	  	 ROYALTY AND PAYMENTS
	  	3
	       2.01
	  	 Royalty Payments
	  	3
	       2.02
	  	 Accrual
	  	4
	       2.03
	  	 Records and Adjustments
	  	4
	       2.04
	  	 Reports and Payments
	  	5
			
	 ARTICLE III
	  	 TERMINATION
	  	5
	       3.01
	  	 Breach
	  	5
	       3.02
	  	 Voluntary Termination
	  	6
	       3.03
	  	 Survival
	  	6
			
	 ARTICLE IV
	  	 MISCELLANEOUS PROVISIONS
	  	6
	       4.01
	  	 Disclaimer
	  	6
	       4.02
	  	 Limited Assignability
	  	6
	       4.03
	  	 Addresses
	  	7
	       4.04
	  	 Taxes
	  	7
	       4.05
	  	 Choice of Law
	  	7
	       4.06
	  	 Integration
	  	7
	       4.07
	  	 Outside the United States
	  	8
	       4.08
	  	 Dispute Resolution
	  	8
	       4.09
	  	 Releases
	  	9

  

 i 

 PATENT LICENSE AGREEMENT 
  
 Effective December 31, 2001, (“Effective Date”) Agere Systems Guardian Corporation (“AGERE”), a Delaware
corporation having an office at 9333 S. John Young Parkway, Orlando, Florida 32819-8698, and INTRALASE CORP., a Delaware corporation, (“INTRALASE”), having an office at 3 Morgan, Irvine, California, 92618, USA, agree as follows*:

  
 ARTICLE I 
 GRANTS OF LICENSES 
  
 1.01 Grant 
  
 (a) AGERE grants to INTRALASE under AGERE’s PATENTS personal, nonexclusive and non-transferable licenses to make, have made, use, lease, sell, offer
to sell and import LICENSED PRODUCTS. 
  
 (b) INTRALASE grants to
AGERE under INTRALASE’s PATENTS personal, nonexclusive, royalty-free and non-transferable licenses to make, have made, use, lease, sell, offer to sell and import LICENSED PRODUCTS. 
  
 1.02 Duration 
  
 All licenses granted herein under any patent shall be in effect from the Effective Date of this Agreement for the duration of the LIMITED PERIOD, unless
terminated sooner pursuant to Article III. 
  
 1.03 Licensing Provisions

  
 (a) The licenses granted herein also include licenses to
(i) make, have made, use and import machines, tools, materials and other instrumentalities, insofar as such machines, tools, materials and other instrumentalities are involved in or incidental to the development, manufacture, testing or repair of
LICENSED PRODUCT(S) which are or have been made, used, leased, owned, sold or imported by or for the grantee of such license; and (ii) convey to any customer of the grantee, with respect to any LICENSED PRODUCT(S) which is sold or leased by such
grantee to such customer, rights to use, resell, or repair such LICENSED PRODUCT(S) as sold or leased by such grantee (whether or not as part of a larger combination); provided, however, that no rights may be conveyed to customers with respect to
any invention which is directed to (1) a combination of such LICENSED PRODUCT (as sold or leased) with any other product, (2) a method or process which is other than the inherent use of such LICENSED PRODUCT itself (as sold or leased), or (3) a
method or process involving the use of a LICENSED PRODUCT to manufacture (including associated testing) any other product. Notwithstanding the foregoing, licenses granted herein to INTRALASE do not include any licenses to make, use, sell, offer for
sale, have made, import, or lease any products to or for any company listed on Appendix B by virtue of being a party in a patent infringement action with AGERE or any of its RELATED COMPANIES. 
  
 (b) Licenses granted herein to INTRALASE are not to be construed either (i)
as consent by the grantor to any act which may be performed by the grantee, except to the extent impacted by a patent licensed herein to the grantee, or (ii) to include licenses to contributorily infringe or induce infringement under U.S. law or a
foreign equivalent thereof. 

	*	Any term in capital letters which is defined in Appendix A shall have the meaning specified therein, otherwise it will have the meaning as used or defined in this Agreement.

 (c) The grant of each license hereunder includes the right to grant sublicenses within the scope of such
license to a party’s RELATED COMPANIES for so long as they remain its RELATED COMPANIES and only to the extent that such RELATED COMPANIES grant to the other party licenses of similar scope and duration as provided in this Agreement. Any such
sublicense granted hereunder may be made effective retroactively, but not prior to the Effective Date hereof, nor prior to the sublicensee’s becoming a RELATED COMPANY of such party. The parties agree that if either party forms a holding
company for patents licensed herein, that party shall cause such holding company to grant licenses under such patents, of the scope and duration granted herein, to the other party. 
  
 (d) The grant of each license hereunder also includes the right of a party to sublicense (commensurate with its own
licenses) any business which is divested by that party or any of its RELATED COMPANIES provided that the sublicense is granted within sixty (60) days of divestiture and the divested business is itself a legal entity at the time of divestiture or
within sixty (60) days thereafter. Such sublicense may continue for so long as the divested business remains a legal entity and shall extend only to the LICENSED PRODUCTS sold or furnished by the divested business prior to the divestiture and only
for the patents of the non-divesting party licensed to the divesting party in this Agreement which are issued as of the date of divestiture. Furthermore, any sublicense shall not extend to the products sold or services furnished by a third party
which acquires the divested business, even if they are of the same kind or similar to those of the divested business and even if made, sold or provided by the divested business. Any payment obligations of a divesting party under this Agreement shall
continue in effect for all LICENSED PRODUCTS, including the LICENSED PRODUCTS of the divested business. The divested business shall be jointly and severally liable with the divesting party for royalties payable on account of the LICENSED PRODUCTS of
the divested business. 
  
 1.04 Ability to Provide Licenses 
  
 (a) It is recognized that certain actions of the parties to this Agreement
may limit their ability to provide licenses hereunder without constituting a breach. In particular, (i) prior to the earliest filing of a patent application disclosing an invention of a party or its RELATED COMPANY, such party or RELATED COMPANY may
assign to a third party the title to patents on such invention, or (ii) prior to the Effective Date of this Agreement, a party or its RELATED COMPANY may have limited by contract its ability to provide licenses hereunder with respect to certain
patents. 
  
 (b) Notwithstanding the provisions of Section
1.04(a), AGERE warrants that it has full rights to grant the licenses set forth herein with respect to U.S. Patents 4860296, 4597638, 5237577, and 5627854, and any reissues, reexaminations, or worldwide equivalents thereof. 
  
 1.05 Joint Inventions 
  
 (a) There are countries (not including the United States) which require the express consent of all inventors or their
assignees to the grant of licenses or rights under patents issued in such countries for joint inventions. 
  

 2 

 (b) Each party shall give such consent, or shall obtain such consent from its RELATED COMPANIES, its
employees or employees of any of its RELATED COMPANIES, as required to make full and effective any such licenses and rights respecting any joint invention granted to the grantee hereunder by such party and by another licensor of such grantee.

  
 (c) Each party shall take steps which are reasonable under the
circumstances to obtain from third parties whatever other consents are necessary to make full and effective such licenses and rights respecting any joint invention purported to be granted by it hereunder. If, in spite of such reasonable steps, such
party is unable to obtain the requisite consents from such third parties, the resulting inability of such party to make full and effective its purported grant of such licenses and rights shall not be considered to be a breach of this Agreement.

  
 1.06 Publicity 
  
 Nothing in this Agreement shall be construed as conferring upon either party
or its RELATED COMPANIES any right to include in advertising, packaging or other commercial activities related to a LICENSED PRODUCT, any reference to the other party (or any of its RELATED COMPANIES), its trade names, trademarks or service marks in
a manner which would be likely to cause confusion or to indicate that such LICENSED PRODUCT is in any way certified by the other party hereto or its RELATED COMPANIES. 
  
 1.07 Confidentiality 
  
 The terms, but not the existence, of this Agreement shall be treated as confidential information by the parties, and neither party shall disclose the
terms or conditions of this Agreement to any third party (other than its RELATED COMPANIES and divested businesses licensed pursuant to this Agreement) without the prior written permission of the other party. Each party, however, shall have (i) the
right to represent to third parties that such party is licensed for the products and patents as provided by this Agreement, and (ii) the right to make disclosures to the extent required by an order of court, regulation of another governmental body,
or otherwise by law or by a stock exchange, provided that the party shall promptly provide written notice to the non-disclosing party of the intended disclosure and of the court order or regulation prior to such disclosure and that the party takes
all reasonable steps to minimize such disclosure by, for example, obtaining a protective order and/or appropriate confidentiality provisions requiring that such information to be disclosed be used only for the purpose for which such law, order,
regulation or requirement was issued. Additionally, each party may disclose this Agreement or its contents to the extent reasonably necessary, under a typical confidentiality expectations, to its accountants, attorneys, financial advisors and in
connection with due diligence activities relating to the sale of the stock or a portion of the business of a party or its RELATED COMPANIES. 
  
 ARTICLE II 
 ROYALTY AND PAYMENTS

  
 2.01 Royalty Payments 
  
 (a) In part payment for the grant of rights hereunder by AGERE to INTRALASE,
INTRALASE shall pay to AGERE the sum of *** within thirty (30) days of EXECUTION. In no event shall such sum or any portion thereof be credited or refunded to INTRALASE. 

	***	Material has been omitted pursuant to a request for confidential treatment. 

  

 3 

 (b) On or before thirty (30) days after EXECUTION, INTRALASE shall pay to AGERE royalties for LICENSED
PRODUCTS sold or leased or otherwise put into use by INTRALASE before December 31, 2001. Such royalties shall be calculated as set forth in Section 2.01(d). 
  
 (c) For each calendar year of this Agreement starting with the year 2002, and in addition to the payment set forth in Section 2.01(a), INTRALASE shall pay
to AGERE a minimum annual payment of ***, to be paid in two equal installments, each on or before January 31 and July 31 of each calendar year. Said payment shall be creditable only towards royalties that accrue during the subsequent twelve (12)
month period. INTRALASE must pay this minimum payment to maintain the license granted herein, even if INTRALASE has no sales or the sales are not sufficient in any one year to generate royalties in an amount equal to the minimum annual payment.
Under no circumstances shall such payment or any portion thereof be refunded to INTRALASE. 
  
 (d) INTRALASE shall pay to AGERE in United States dollars a fixed-sum of *** for each LICENSED PRODUCT sold or leased or otherwise put into use by INTRALASE or any of its RELATED COMPANIES. This royalty fee shall be
applied to both (1) product sold prior to December 31, 2001 (pursuant to Section 2.01(b)), and (2) product sold after December 31, 2001. 
  
 2.02 Accrual 
  
 (a) Royalty shall accrue on any LICENSED PRODUCT upon sale, lease, or otherwise put into use and shall become payable in accordance with the provisions of
Section 2.04. Obligations to pay accrued royalties shall survive termination of licenses and rights pursuant to Section 1.02 and ARTICLE III. 
  
 (b) When a company ceases to be a RELATED COMPANY of INTRALASE, royalties which have accrued with respect to any products of such company, but which have
not been paid, shall become payable with INTRALASE’s next scheduled royalty payment. 
  
 (c) Notwithstanding any other provisions hereunder, royalties shall accrue and be payable only to the extent that enforcement of INTRALASE’s obligation to pay such royalties would not be prohibited by applicable
law. 
  
 2.03 Records and Adjustments 
  
 (a) INTRALASE shall keep full, clear and accurate records with respect to
all LICENSED PRODUCTS and shall furnish any information which AGERE may reasonably prescribe from time to time to enable AGERE to ascertain the proper royalty due hereunder on account of products sold, leased and put into use by INTRALASE or any of
its RELATED COMPANIES. INTRALASE shall retain such records with respect to each LICENSED PRODUCT for at least five (5) years from the sale, lease or putting into use of such LICENSED PRODUCT. AGERE shall have the right through its accredited
auditors no more than once every year to make an examination after notice of at least thirty (30) days, during normal business hours, of all records and accounts bearing upon the amount of royalty payable to it hereunder. Prompt adjustment shall be
made to compensate for any errors or omissions disclosed by such examination, provided AGERE gives INTRALASE notice, in writing, of such underpayment within thirty (30) days of the completion of such audit. Such notice shall contain the report of
such auditors and shall include the data which formed the 

	***	Material has been omitted pursuant to a request for confidential treatment. 

  

 4 

 basis for such underpayment calculation. AGERE shall be responsible for all its costs of an audit unless the audit
revealed an underpayment by INTRALASE of at least ten percent (10%) for the audited period. In such an event, INTRALASE shall be responsible for AGERE’s reasonable out-of-pocket costs for such accredited auditors to conduct the audit.

  
 (b) Independent of any such examination, AGERE will credit to
INTRALASE the amount of any overpayment of royalties made in error which is identified and fully explained in a written notice to AGERE delivered within twelve (12) months after the due date of the payment which included such alleged overpayment,
provided that AGERE is able to verify, to its own satisfaction, the existence and extent of the overpayment. 
  
 (c) No refund, credit or other adjustment of royalty payments shall be made by AGERE except as provided in Sections 2.01(c) and 2.03. Rights conferred by
this Section 2.03 shall not be affected by any statement appearing on any check or other document, except to the extent that any such right is expressly waived or surrendered by a party having such right and signing such statement. 
  
 2.04 Reports and Payments 
  
 (a) Within sixty (60) days after the end of each semiannual period ending on
June 30th or December 31st, commencing with the semiannual period during which this Agreement becomes effective, INTRALASE shall furnish to AGERE at the address specified in Section 4.03 a statement certified by a responsible official of INTRALASE
showing in a manner acceptable to AGERE the number of LICENSED PRODUCTS sold or leased or otherwise put into use by INTRALASE Section 2.01(c) and the net amount payable after application of such credit. 
  
 If no LICENSED PRODUCT has been sold the statement shall show that fact. 
  
 (b) Within such sixty (60) days INTRALASE shall pay in United States dollars
to AGERE at the address specified in Section 4.03 the royalties payable in accordance with such statement. Any conversion to United States dollars shall be at the prevailing rate for bank transfers as quoted for the last day of such semiannual
period by leading United States banks in New York City dealing in the foreign exchange market. 
  
 (c) Overdue payments hereunder shall be subject to a late payment charge calculated at an annual rate of three percentage points (3%) over the prime rate or successive prime rates (as posted in New York City) during
delinquency. If the amount of such charge exceeds the maximum permitted by law, such charge shall be reduced to such maximum. 
  
 ARTICLE III 
 TERMINATION

  
 3.01 Breach 
  
 In the event of a breach of this Agreement by either party, the other party
may, in addition to any other remedies that it may have, at any time terminate all licenses and rights granted by it hereunder by not less than six (6) months written notice specifying such breach, unless within the period of such notice all
breaches specified therein shall have been remedied. 
  

 5 

 3.02 Voluntary Termination 
  
 Either party may voluntarily terminate all or a specified portion of the licenses and rights granted to it hereunder by
providing at least two (2) months prior written notice of such termination. Such notice shall specify any affected patent, invention or product. 
  
 3.03 Survival 
  
 (a) If a company ceases to be a RELATED COMPANY of a party, licenses and rights granted hereunder with respect to patents of such company on inventions
made prior to the date of such cessation, shall not be affected by such cessation. 
  
 (b) Any termination of licenses and rights of a party under the provisions of this Article III shall not affect such party’s licenses, rights and obligations with respect to any LICENSED PRODUCTS made or
furnished prior to such termination, and shall not affect the other party’s licenses and rights (and obligations related thereto) hereunder. 
  
 ARTICLE IV 
 MISCELLANEOUS PROVISIONS

  
 4.01 Disclaimer 
  
 Other than the provisions of Section 1.04, neither party nor any of its
RELATED COMPANIES makes any representations, extends any warranties of any kind, assumes any responsibility or obligations whatever, or confers any right by implication, estoppel or otherwise, other than the licenses, rights and warranties herein
expressly granted. 
  
 4.02 Limited Assignability 
  
 The parties hereto have entered into this Agreement in contemplation of
personal performance, each by the other, and intend that the licenses and rights granted hereunder to a party not be extended to entities other than such party’s RELATED COMPANIES without the other party’s express written consent. All of
AGERE’s rights, title and interest in this Agreement and any licenses and rights granted to it hereunder may be assigned to Agere Systems Inc., and any direct or indirect successor to the business of Agere Systems Inc. that is relevant to the
business or subject matter of this Agreement as the result of any internal reorganization, which successor shall thereafter be deemed substituted for AGERE as the party hereto, effective upon such assignment; but neither this Agreement nor any
licenses or rights hereunder shall be otherwise assignable or transferable (in insolvency proceedings, by reason of a corporate merger, or otherwise) by either party without the express written consent of the other party. Notwithstanding the
foregoing, INTRALASE may assign all of its rights under this Agreement to a purchaser of all or substantially all of INTRALASE’s business of developing, manufacturing and selling the LICENSED PRODUCTS or to a RELATED COMPANY of INTRALASE or
pursuant to a merger or consolidation of INTRALASE or a RELATED COMPANY of INTRALASE or pursuant to an acquisition of the entire interest in INTRALASE or a RELATED COMPANY of INTRALASE through a stock transaction, without the consent of AGERE,
provided, however, only (i) for the duration and term of licenses as specified in this Agreement, (ii) to the extent and for the time the business functions as a separately identifiable business (iii) for LICENSED PRODUCTS of the kind provided by
the business prior to its divestiture or acquisition and not to any products or services of any entity which acquires the 
  

 6 

 divested business, (iv) so long as the entity which acquires the divested business is not in an intellectual property
dispute with AGERE or any of its SUBSIDIARIES, and (v) such purchaser or RELATED COMPANY (as applicable) agrees in writing to be bound by all of INTRALASE’S obligations herein. 
  
 4.03 Addresses 
  
 (a) Any notice or other communication hereunder shall be sufficiently given to INTRALASE when sent by overnight or certified mail to the address set out
above or to AGERE when sent by overnight or certified mail addressed to Contract Administrator, Agere Systems Guardian Corporation, 9333 South John Young Parkway, Orlando, Florida 32819-8698 United States of America. Changes in such addresses may be
specified by written notice. 
  
 (b) Payments by INTRALASE shall
be made to AGERE at Chase Manhattan Bank, Account ***, General Post Office, P.O. Box 26641, New York, New York 10087-6641, United States of America. Alternatively, payments to AGERE may be made by bank wire transfers to AGERE’S account. Agere
Systems Guardian Corporation, Account ***, Chase Manhattan Bank, 55 Water Street, New York, New York, 10041 United States of America, ABA Code: 021000021, Swift Code: CHASUS33. Changes in such address or account may be specified by written notice.

  
 4.04 Taxes 
  
 INTRALASE shall bear all taxes, duties, levies and similar charges (and any
related interest and penalties), however designated, imposed as a result of the existence or operation of this Agreement, except (i) any tax imposed upon AGERE in a jurisdiction other than the United States if such tax is allowable as a credit
against the United States income taxes of AGERE; and (ii) any net income tax imposed upon AGERE by the United States or any governmental entity within the United States (the fifty (50) states and the District of Columbia). In order for the exception
contained in (i) to apply, INTRALASE must furnish AGERE with evidence issued by the taxing authority in such jurisdiction that such tax has been paid. The evidence must be furnished within thirty (30) days of issuance by the taxing authority and
must be sufficient to satisfy United States taxing authorities that such tax has been paid. 
  
 4.05 Choice of Law 
  
 The
parties are familiar with the principles of New York commercial law, and desire and agree that the law of New York, exclusive of its conflict of law provisions, shall apply in any dispute arising with respect to this Agreement. 
  
 4.06 Integration 
  
 This Agreement sets forth the entire agreement and understanding between the parties as to the subject matter hereof and
merges all prior discussions between them. Neither of the parties shall be bound by any modifications, warranties, understandings or representations with respect to such subject matter other than as expressly provided herein or in a writing signed
with or subsequent to execution hereof by an authorized representative of the party to be bound thereby. 

	***	Material has been omitted pursuant to a request for confidential treatment. 

  

 7 

 4.07 Outside the United States 
  
 (a) There are countries in which the owner of an invention is entitled to compensation, damages or other monetary award for
another’s unlicensed manufacture, sale, lease, use or importation involving such invention prior to the date of issuance of a patent for such invention but on or after a certain earlier date, hereinafter referred to as the invention’s
“protection commencement date” (e.g., the date of publication of allowed claims or the date of publication or “laying open” of the filed patent application). In some instances, other conditions precedent must also be fulfilled
(e.g., knowledge or actual notification of the filed patent application). The parties agree that (i) an invention which has a protection commencement date in any such country may be used in such country pursuant to the terms of this Agreement on and
after any such date, and (ii) all such conditions precedent are deemed satisfied by this Agreement. 
  
 (b) There may be countries in which a party hereto may have, as a consequence of this Agreement, rights against infringers of the other party’s
patents licensed hereunder. Each party hereby waives any such right it may have by reason of any third party’s infringement or alleged infringement of any such patents. 
  
 (c) INTRALASE hereby agrees to register or cause to be registered, to the extent required by applicable law, and without
expense to AGERE or any of its RELATED COMPANIES, any agreements wherein sublicenses are granted by it under AGERE’s PATENTS. INTRALASE hereby waives any and all claims or defenses, arising by virtue of the absence of such registration, that
might otherwise limit or affect its obligations to AGERE. 
  
 4.08 Dispute
Resolution 
  
 (a) If a dispute arises out of or relates to
this Agreement, or the breach, termination or validity thereof, the parties agree to submit the dispute to a sole arbitrator agreed upon by the parties within thirty (30) days of the beginning of the selection process, or in the absence of such
agreement, to AAA arbitration using a single arbitrator which shall be governed by the United States Arbitration Act. 
  
 (b) Any award made (i) shall be a bare award limited to a holding for or against a party and affording such remedy as is deemed equitable, just and within
the scope of the Agreement; (ii) shall be without findings as to issues (including but not limited to patent validity and/or infringement) or a statement of the reasoning on which the award rests; (iii) may in appropriate circumstances (other than
patent disputes) include injunctive relief; (iv) shall be made within four (4) months of the appointment of the arbitrator; and (v) may be entered in any court. 
  

(c) The requirement for arbitration shall not be deemed a waiver of any right of termination under this Agreement and the arbitrator is not empowered
to act or make any award other than based solely on the rights and obligations of the parties prior to any such termination. 
  
 (d) The arbitrator shall be knowledgeable in the legal and technical aspects of this Agreement and shall determine issues of arbitrability but may not
limit, expand or otherwise modify the terms of the Agreement. 
  
 (e) The place of arbitration shall be New York City. 
  

 8 

 (f) Each party shall bear its own expenses but those related to the compensation and expenses of the
arbitrator shall be borne equally. 
  
 (g) A request by a party to
a court for interim measures shall not be deemed a waiver of the obligation to arbitrate. 
  
 (h) The arbitrator shall only have authority to award compensatory damages, there is no authority to award punitive or other damages and each party irrevocably waives any claim thereto. 
  
 (i) The parties, their representatives, other participants and the mediator
and arbitrator shall hold the existence, content and result of arbitration in confidence. 
  
 4.09 Releases 
  
 (a)
After receipt of payments to AGERE under Sections 2.01(a) and (b), AGERE, for itself and for its RELATED COMPANIES, and subject to Section 4.09(c), hereby releases, to the extent of its right to do so, INTRALASE and its RELATED COMPANIES under any
patent infringement arising prior to the Effective Date of this Agreement for which the rights and licenses expressly granted under this Agreement to INTRALASE and its RELATED COMPANIES would be a complete defense had this Agreement been in effect
at the time such patent infringement arose. 
  
 (b) INTRALASE, for
itself and for its RELATED COMPANIES, hereby releases, to the extent of its right to do so, AGERE and its RELATED COMPANIES, and subject to the provisions of Section 4.09(c), under any patent infringement arising prior to the Effective Date of this
Agreement for which the rights and licenses expressly granted under this Agreement to AGERE and its RELATED COMPANIES would be a complete defense had this Agreement been in effect at the time such patent infringement arose. 
  
 (c) The releases in this Section 4.09 shall not operate with respect to
acquisitions of any sort during the LIMITED PERIOD. That is, if during the LIMITED PERIOD, a party or its RELATED COMPANIES, individually or collectively, acquire one or more companies, or the business or assets or any portion thereof of one or more
companies or other entities, then engaged in whole or in part in the business of making, importing, selling, using or leasing products and/or services of the kinds which are furnished or used by a party or any of its RELATED COMPANIES in the
operation of the business in which they are engaged as of that party’s signing of this Agreement, but such companies or entities were not part of either party or its RELATED COMPANIES as of such party’s signing of this Agreement, then such
companies or entities shall not be covered by the releases granted in Section 4.09. The releases granted in this Section 4.09 to either party and its RELATED COMPANIES shall not operate to release any such customers who are parties in a patent
infringement action with such party or any of its RELATED COMPANIES as of two weeks prior to the Effective Date of this Agreement. 
  
 IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed in duplicate originals by its duly authorized representatives on
the respective dates entered below. 
  

					
	 	 	AGERE SYSTEMS GUARDIAN CORPORATION
			
	 	 	By:	 	/s/    GERARD A. DEBLASI        
			
	 	 	Date:	 	January 16, 2002

  

 9 

	
	
	 INTRALASE CORP.

	
	 By:  /s/    J. RANDY ALEXANDER

	
	 Date:   January 15, 2002

  
 THIS AGREEMENT DOES
NOT BIND OR OBLIGATE EITHER PARTY 
 IN ANY MANNER UNLESS DULY EXECUTED BY AUTHORIZED 
 REPRESENTATIVES OF BOTH PARTIES. 
  

 10 

 APPENDIX A 
 DEFINITIONS 
  
 AGERE’s PATENTS means all patents (including utility models but excluding design patents and design registrations) issued or having enforceable rights in any country of the world from an application filed as of the Effective
Date, which AGERE (or any company while a wholly-owned SUBSIDIARY of Agere Systems Inc.), as of the Effective Date and extending through the LIMITED PERIOD, has the right to grant any licenses of the type herein granted, but only to the extent of
such right. 
  
 INTRALASE’S PATENTS means all patents
(including utility models but excluding design patents and design registrations) issued or having enforceable rights in any country of the world from an application filed as of the Effective Date which INTRALASE (or any company while a wholly-owned
SUBSIDIARY of INTRALASE), as of the Effective Date and extending through the LIMITED PERIOD has the right to grant any licenses of the type herein granted, but only to the extent of such right. 
  
 EXECUTION means the date the last party signs this Agreement.

  
 LASER OSCILLATOR SUBSYSTEM means a functional laser
subsystem for generating optical pulse energy and having at least the following: 1) a laser configured to operate in a mode-locked or Q-switched fashion; and 2) a saturable absorber. 
  
 LICENSED PRODUCTS means, as to INTRALASE, any LASER OSCILLATOR SUBSYSTEM for use in or with medical laser equipment
or University-based research for which a royalty has been paid, and, as to AGERE, semiconductor devices, laser devices, combinations of said devices, non-medical systems incorporating said devices and combinations, and non-medical applications.

  
 LIMITED PERIOD means the period commencing on the
Effective Date of this Agreement and continuing for seven (7) years thereafter. 
  
 RELATED COMPANIES means with respect to INTRALASE, its SUBSIDIARIES and with respect to AGERE, means its SUBSIDIARIES, its parent, Agere Systems Inc. and SUBSIDIARIES of Agere Systems Inc., with the exception
of AGERE. 
  
 SUBSIDIARY of a company means a corporation
or other legal entity (i) the majority of whose shares or other securities entitled to vote for election of directors (or other managing authority) is now or hereafter controlled by such company either directly or indirectly; or (ii) which does not
have outstanding shares or securities but the majority of whose ownership interest representing the right to manage such corporation or other legal entity is now or hereafter owned and controlled by such company either directly or indirectly; but
any such corporation or other legal entity shall be deemed to be a SUBSIDIARY of such company only as long as such control or ownership and control exists. 
  

 A-1 

 APPENDIX B 
  

Multiplex Inc. 
  
 Proxim Inc. 
  

 B-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}]]